(S)-O-methylleucinol | 64715-91-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (S)-O-methylleucinol
• 英文别名: leucinol methyl ether；(S)-(-)-1-Methoxy-2-amino-4-methylpentan；1S-methoxymethyl-3-methyl-butylamine；(S)-1-isobutyl-2-methoxyethylamine；(S)-1-methoxy4-methylpentan-2-amine；(2S)-1-methoxy-4-methylpentan-2-amine
• CAS: 64715-91-9
• 化学式: C₇H₁₇NO
• 分子量: 131.218
• InChiKey: CMMWLDUVRGBDBR-ZETCQYMHSA-N

物化性质

• 沸点：
  168.3±13.0 °C(Predicted)
• 密度：
  0.847±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-O-methylleucinol 在 三氟乙酸 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 46.0h， 生成 di-tert-butyl 1-<(R)-1,2,3,4-tetrahydro-1-<(S)-1-methoxymethyl-3-methylbutylimino>-2-naphthyl>-1,2-hydrazinedicarboxylate
  参考文献：
  名称：

  Asymmetric synthesis of β-aminotetralins by electrophilic amination

  摘要：

  An effective synthesis of beta-aminotetralins (6) including an asymmetric electrophilic amination by di-t-butyl azodicarboxylate is reported. Depending on the chiral auxiliaries (S)-7a-d, the central intermediates 9 and 10 could be isolated in 62-80% de. Subsequent hydrolysis and reductive degradation resulted in the nonracemic final products 6 (57-84% ee). Separation of the diastereomeric intermediates by chromatography makes possible the synthesis of optically pure products. An induction model for the asymmetric amination is provided.

  DOI：

  10.1016/s0040-4020(01)85702-1
• 作为产物：
  描述：

  N-苄氧羰基-L-亮氨醇 在 palladium on activated charcoal 、 氢气 、 sodium hydride 作用下， 以 甲醇 为溶剂， 反应 29.0h， 生成 (S)-O-methylleucinol
  参考文献：
  名称：

  Discovery of (S)-4-isobutyloxazolidin-2-one as a novel leucyl-tRNA synthetase (LRS)-targeted mTORC1 inhibitor

  摘要：

  A series of leucinol analogs were investigated as leucyl-tRNA synthetase-targeted mTORC1 inhibitors. Among them, compound 5, (S)-4-isobutyloxazolidin-2-one, showed the most potent inhibition on the mTORC1 pathway in a concentration-dependent manner. Compound 5 inhibited downstream phosphorylation of mTORC1 by blocking leucine-sensing ability of LRS, without affecting the catalytic activity of LRS. In addition, compound 5 exhibited cytotoxicity against rapamycin-resistant colon cancer cells, suggesting that LRS has the potential to serve as a novel therapeutic target. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.05.011

文献信息

• ORGANIC COMPOUNDS
  申请人：Baettig Urs

  公开号：US20100029670A1

  公开（公告）日：2010-02-04

  The present invention relates to compounds of formula (I) wherein X, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  本发明涉及以下式（I）的化合物 其中X，R1，R2，R3，R4和R5如本文所定义，这些化合物对于治疗对CXCR2受体介质有响应的疾病是有用的。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• Certain sulfonamide heterobicyclic platelet activating factor antagonists
  申请人：British Bio-Technology Limited

  公开号：US05180723A1

  公开（公告）日：1993-01-19

  Compounds of general formula I; ##STR1## wherein: A.sup.1 is .dbd.N--, .dbd.CH-- or .dbd.CR.sup.1 --; A.sup.2 is .dbd.N--, .dbd.CH-- or .dbd.CR.sup.2 --; provided that, when one of A.sup.1 and A.sup.2 is a nitrogen atom, the other of A.sup.1 and A.sup.2 is other than a nitrogen atom; wherein the other variables are as defined in the specification and their pharmaceutically and veterinarily acceptable acid addition salts and hydrates are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or disorders mediated by PAF.

  通式I的化合物；其中：A.sup.1为.dbd.N--，.dbd.CH--或.dbd.CR.sup.1--; A.sup.2为.dbd.N--，.dbd.CH--或.dbd.CR.sup.2--; 前提是，当A.sup.1和A.sup.2中的一个是氮原子时，另一个不是氮原子；其中其他变量如规范中定义的那样，它们的药用和兽医学可接受的酸盐和水合物是血小板活化因子（PAF）的拮抗剂，因此在治疗或改善由PAF介导的各种疾病或紊乱方面是有用的。
• P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor
  作者：Brian L. Venables、Ny Sin、Alan Xiangdong Wang、Li-Qiang Sun、Yong Tu、Dennis Hernandez、Amy Sheaffer、Min Lee、Cindy Dunaj、Guangzhi Zhai、Diana Barry、Jacques Friborg、Fei Yu、Jay Knipe、Jason Sandquist、Paul Falk、Dawn Parker、Andrew C. Good、Ramkumar Rajamani、Fiona McPhee、Nicholas A. Meanwell、Paul M. Scola

  DOI：10.1016/j.bmcl.2018.04.009

  日期：2018.6

  A series of tripeptidic acylsulfonamide inhibitors of HCV NS3 protease were prepared that explored structure-activity relationships (SARs) at the P4 position, and their in vitro and in vivo properties were evaluated. Enhanced potency was observed in a series of P4 ureas; however, the PK profiles of these analogues were less than optimal. In an effort to overcome the PK shortcomings, modifications to

  制备了一系列HCV NS3蛋白酶的三肽酰基磺酰胺抑制剂，探索了P4位置的结构-活性关系（SAR），并评估了它们的体外和体内特性。在一系列P4脲中观察到了增强的效力；然而，这些类似物的PK曲线不是最佳的。为了克服PK的缺点，对P3-P4结进行了修改。这包括其中两个尿素NH基团之一被N-甲基化或被氧原子取代的策略。前一种方法提供了一系列区域异构的N-甲基化尿素，而后者则产生了P4反向氨基甲酸酯，它们都保留了强大的NS3抑制特性，同时依赖于替代的H键供体拓扑。
• A comparison of secondary and tertiary amides as directors of ortho and adjacent benzylic lithiation and of asymmetric induction in ortho lithiated benzamides
  作者：Peter Beak、Anthony Tse、Joel Haawkins、Chin-Wen Chen、Sander Mills

  DOI：10.1016/s0040-4020(01)91916-7

  日期：1983.1

  Comparisons are made between the influence of secondary and tertiary amides on ortho and adjacent benzylic metallations of benzamides. In the intramolecular competition offered by N,N-diethyl-N-ethylterephthalamide (1) the tertiary amide is the more effective director of ortho lithiation, while the secondary amide is better in the intermolecular competitions offered by the pairs N-ethyl-(9): N,N-diethylbenzamide(10)

  比较仲酰胺和叔酰胺对苯甲酰胺的邻位和邻位苄基金属化的影响。在N，N-二乙基-N-乙基对苯二甲酰胺（1）提供的分子内竞争中，叔酰胺是邻位锂化的更有效导向器，而仲酰胺在N-乙基-（9 ）：N，N-二乙基苯甲酰胺（10）和N-异丙基-（11）：N，N-二异丙基苯甲酰胺（12）。在2-异丙基苯甲酰胺25和26中，仲酰胺和叔酰胺都可以直接金属化到酰胺上; 然而，在仲2-乙基和2-甲基苯甲酰胺中发现苄基金属化21和22以及叔2-乙基苯甲酰胺19。注意到19的抗-N-亚甲基的磁性不等价。内硫基（S）-O-甲基-N-苯甲酰亮氨醇（34）与1-萘甲醛-1-d的反应在内酯化后得到3-（1-萘-1-d）-邻苯二甲酸酯与10％对映异构体过量的。通过在环化之前分离非对映异构体，可以以高对映体纯度获得邻苯二甲酰亚胺。对照实验确定观察到的不对称诱导归因于非对映异构过渡态。相应的叔苯甲酰胺在诱导不对称方面无效。为这些观察提供了结构和机械原理。
• Production of certain imidazopyridinyl-methyl-benzene sulfonamides
  申请人：British Bio-Technology Limited

  公开号：US05276153A1

  公开（公告）日：1994-01-04

  Compounds of general formula I; ##STR1## wherein: A.sup.1 is .dbd.N--, .dbd.CH-- or .dbd.CR.sup.1 --; A.sup.2 is .dbd.N--, .dbd.CH-- or .dbd.CR.sup.2 --; provided that, when one of A.sup.1 and A.sup.2 is a nitrogen atom, the other of A.sup.1 and A.sup.2 is other than a nitrogen atom; wherein the rest of the variables are defined in the specification; and their pharmaceutically and veterinarily acceptable acid addition salts and hydrates are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or disorders mediated by PAF.

  通式I的化合物；其中：A.sup.1是.dbd.N--，.dbd.CH--或.dbd.CR.sup.1--; A.sup.2是.dbd.N--，.dbd.CH--或.dbd.CR.sup.2--; 前提是，当A.sup.1和A.sup.2中的一个是氮原子时，另一个不是氮原子; 其中其余的变量在规范中定义; 它们的药学和兽医可接受的酸盐和水合物是血小板活化因子（PAF）的拮抗剂，因此可用于治疗或改善由PAF介导的各种疾病或障碍。